Objectives. RANK ligand (RANKL) is involved in destruction and osteoporosis in RA. In this study, the relationships between RANKL and ACPA, anti-carbamylated protein antibodies (anti-CarP), cytokines and chemokines were analysed in individuals before the onset of RA symptoms, and their associations with radiological findings at disease onset were assessed.
Introduction
RA is a chronic inflammatory disease characterized by inflammation in the joints that often leads to destruction of the cartilage and bone [1, 2] . Bone resorption in patients with RA is suggested to be enhanced by the inflammatory process in the joints preferentially in the presence of ACPA and RF [36] . Approximately half of all patients have radiographically detectable bone erosions during the first years of the disease, and it has been suggested that this process might start several years before the clinical onset of arthritis in ACPA-positive individuals [7] .
RANK ligand (RANKL), a key molecule of osteoclast maturation and activation, is essential for the progression of bone damage in inflammatory joint disease [8, 9] . Osteoblasts are the primary source of RANKL, but immune and synovial cells also express RANKL [10] . Several pro-inflammatory cytokines (namely TNF-a, IL-1, IL-6 and IL-17) are involved in increasing the expression of RANKL [11] . ACPA have been shown to increase the number of osteoclast precursors by binding to their surface and to trigger the production of, for example, TNF-a [12] . Antibodies against citrullinated vimentin have been directly linked to osteoclast differentiation and bone resorption in RA, as has been shown both in vivo and in vitro [12] . Recently, elevated RANKL concentrations have been associated with ACPA and particularly anti-citrullinated vimentin (amino acids 6075)-positive patients with early untreated RA [13] and have also been associated with bone destruction and with radiological progression after 2 years in early RA [14] . We and others have reported that anti-carbamylated (CarP) antibodies were associated with worse radiological progression in patients with early RA, independent of ACPA status [1517] .
Given that ACPA, anti-CarP antibodies and RANKL play a significant role in RA-specific bone damage, and ACPA may develop many years before disease onset and precede the destructive process by several years, we have investigated the relationships between RANKL and ACPA, anti-CarP antibodies and inflammatory markers measured as pro-inflammatory and anti-inflammatory cytokines and chemokines in individuals before the onset of symptoms of RA. Furthermore, the association of these biomarkers with bone destruction has been evaluated in the same individuals after disease onset. We have also taken advantage of our previously analysed ACPA specificities and anti-CarP antibodies from the same time points as RANKL have been analysed for this study [15, 18] .
Methods

Study population
The cases included in this study were identified by coanalysis of the register of the patients fulfilling the 1987 ARA classification criteria for RA [19] at the Department of Rheumatology, University Hospital, Umeå and the registers at the Medical Biobank of Northern Sweden. Four hundred and seventy individuals [136 men and 334 women, mean (S.D.) age 52.3 (9.4) years], referred to as pre-symptomatic individuals, and 96 controls [36 men and 60 women, mean (S.D.) age 53.2 (9.7) years] from the same cohorts were identified. The median pre-dating time until the onset of symptoms of the subsequent RA disease was 5.0 (interquartile range 5.1) years. The participant recruitment, blood sampling and storage conditions (À80  C) have been presented previously [20] . The controls were matched based on group level for sex and age.
Smoking status was defined as ever being a smoker (i.e. both former and current smokers) or a non-smoker. Of the pre-symptomatic individuals, 63.5% were smokers compared with 37.9% of the control subjects. Of the pre-symptomatic individuals, 158 were assessed with radiographs of hands and feet when diagnosed with RA at the early arthritis clinic. HLA-shared epitope (SE) was present in 65.5% of the cases, defined as HLA -DRB1*0401/0404/0405/0408/0101 and genotyped as described previously [21] . Detailed demographic data of the study population are presented in supplementary Table S1 , available at Rheumatology Online. The participants gave their written informed consent, and the Regional Ethics Committee at Umeå University approved the study.
Laboratory analyses
The plasma concentration of the total (free and bound) RANKL was measured using the Human RANKL ELISA (BioVendor, Karasek, Czech Republic) in accordance with the manufacturer's protocol. A cut-off value for RANKL positivity was defined using the receiver operating characteristic curve, yielding a cut-off value for positivity >0.927 nmol/l, with a specificity of 97.9%. All samples were re-analysed by adding a commercial blocker (HeteroBlock; Omega Biologicals, Inc., Mozeman, MT, USA) to avoid false-positive results in RF-positive individuals. The results of the sample analysis for controls, RF-positive and negative pre-symptomatic individuals correlated significantly with the measurements without a blocker (P < 0.001 for all analyses), although all measurements using a blocker decreased the concentrations overall. Thus, the results from the original analysis without the blocker will be presented.
The concentrations of cytokines/chemokines IL-6, IL-10, IL-2, IL-4, IL-8, eotaxin, monocyte chemoattractantprotein-1, macrophage-derived chemokine and IFN-g-inducible protein 10 (IP-10) were determined using the Chemokine Panel 1 (human) Kits (K15047D) and the Proinflammatory Panel 1 (Human) Kits (K15049D), Meso Scale Discovery V-plex methods (Rockville, MD, USA).
The results of plasma samples included in this study were also analysed for ACPA, measured as anti-CCP2 IgG, according to the manufacturer's instructions (Euro Diagnostica, Malmö , Sweden). The results for the four different ACPA finespecificities anti-fibrinogenb36-52 (cFibb36-52, citrullinated at position 44), anti-a-enolase5-21 (CEP-1, citrullinated at position 9 and 15), anti-filaggrin307-324 (CCP-1, citrullinated at position 13) and anti-vimentin60-75 (cVim60-75, citrullinated at positions 64, 69 and 71) as previously described using a microarray based on the ImmunoCAP ISAC system (Phadia AB, Uppsala, Sweden) were included [18] . The frequencies of positivity were 26.5% for anti-cFib36-52, 25.5% for anti-CEP-1, 21.9% for anti-cfilaggrin and 9.2% for anti-cVim60-75 antibodies, respectively. The anti-carbamylated protein (CarP) antibodies were determined using an in-house ELISA as described previously, with 11.7% positivity among the cases (supplementary data, available at Rheumatology Online; Table S1 ) [15, 16] . Analysis of RF of www.rheumatology.oxfordjournals.org
IgM isotype was performed using the EliA assay on the Phadia 2500-system according to the manufacturer's instructions (Phadia GmbH, Freiburg, Germany). The cut-off value was the optimum for sensitivity with a specificity of 96%, yielding a frequency of 28.6% positivity in the presymptomatic individuals (supplementary data, available at Rheumatology Online; Table S1 ).
Evaluation of radiographs
Radiographs of hands, wrists and feet were performed for 158 individuals at the time of diagnosis (baseline) with early RA, on average 7 months after symptom onset. The radiographs were graded in consensus according to the Larsen score [22] by two rheumatologists specifically trained in the evaluation of radiographs and who were unaware of the results of other analysed factors. The Larsen score at baseline, for the individuals when they were diagnosed with RA, was mean (S.E.M.) 6.5 (0.4).
Statistical analysis
Continuous data were either compared with the nonparametric KruskalWallis test for several groups or the MannWhitney U-test when comparing two groups. Correlation analysis was performed using Spearman's rank correlation test. Logistic regression analysis was used to identify associations between RANKL and risk factors in the development of RA. Univariate analysis of variance was used for calculation of the RANKL concentration in relationship to the Larsen score at baseline. Any adjustments of data were based on previously performed studies and subsequent hypothesis. Associations are presented as odds ratios with 95% CI, and P 4 0.05 was considered as statistically significant. All statistical analyses were performed using SPSS 23.0 software (Chicago, IL, USA).
Results
RANKL response in pre-symptomatic individuals and the development over time in relationship to ACPA/RF The concentration of RANKL was significantly higher in the pre-symptomatic individuals compared with the controls [mean (S.E.M.) 0.50 (0.03) vs 0.21 (0.02) nmol/l; P < 0.001; Fig. 1 ] and was found to increase gradually during the pre-dating time (P < 0.001; Fig. 2 ).
The frequency of RANKL occurring above the cut-off was 13.4% in the pre-symptomatic individuals and 2.1% in controls. The accumulated frequency of RANKL positivity increased constantly during the time pre-dating symptom onset and followed the same response as the classical ACPA (e.g. anti-cFibb36-52, anti-cVim60-75, anti-CEP-1, anti-cfilaggrin and anti-CCP2; Fig. 3A) . In samples collected 55 and 58 years before the onset of symptoms, 6.8 and 8.0%, respectively, were RANKL positive, whereas the corresponding figures for anti-CCP2 antibodies were significantly higher, 25.8 and 24.1% positivity, respectively (P < 0.001and P < 0.05) and for RF 22.5 and 17.9% (P < 0.001 and P < 0.05). Of the ACPA specificities, anti-cFibb36-52 or anti-cfilaggrin antibodies both occurred with 18.2% positivity 58 years before symptom onset and anti-cFibb36-52 IgG with 19.6% positivity 55 years pre-dating symptom onset (P < 0.05; Fig. 3B) . It was not possible to perform corresponding statistical calculation of the frequencies for RANKL in comparisons with the frequencies of positivity 55 or 58 years pre-dating onset of symptoms for anti-cVim60-75 and anti-CEP-1 and 55 years for anti-cfilaggrin antibodies because of low numbers. The first positive sample of RANKL appeared 10.5 years before symptom onset of RA. This was in contrast to anti-CCP2, anti-cfilaggrin, anti-cFibb36-52, anti-cVim60-75 and anti-CEP-1 antibodies or RF positivity, all of which appeared with the first positive sample 513 years before symptom onset, or anti-CarP antibody, which appeared 511 years pre-dating onset (Fig. 3B) . 
RANKL in relationship to pro-inflammatory cytokines
In pre-symptomatic individuals, the concentration of RANKL was correlated with both IL-6 and IL-10 concentrations (r s = 0.10, P < 0.05 and r s = 0.13, P < 0.01, respectively). Table 1 ). The association between RANKL and the development of RA in pre-symptomatic individuals did not remain significant after adjusting for anti-CCP2 antibodies (Table 1) . Adjustments for RF or HLA-SE carriage could not be performed because data for the controls were not available.
RANKL in relationship to radiological findings
The RANKL concentration before onset of symptoms of RA was not related to the Larsen score at baseline (P = 0.26). Although, when stratified for sex, the RANKL concentration was related to the Larsen score at baseline in men (r s = 0.31, P < 0.05), the significance did not remain when adjusting for the presence of anti-CCP2 antibodies, anti-CarP antibodies, RF or age, respectively; however, the association remained significant after adjusting for anti-cVim60-75 antibodies. Positivity for anti-CarP antibodies was associated with increased radiological damage as detected by a higher Larsen score at baseline in pre-symptomatic individuals, mean (S.E.M.) 10.1 (2.0) compared with 6.6 (0.6) in antiCarP IgG-negative individuals [b = 3.46 (95% CI: 0.05, 6.87), P < 0.05]. Positivity for ACPA (anti-CCP2, anticFibb36-52, anti-CEP-1, anti-cfilaggrin and anti-cVim60-75 antibodies) was not associated with a higher Larsen score at baseline. The combination of being positive for both RANKL and anti-CarP antibodies showed a stronger association with the Larsen score at baseline [b = 6.18 (95% CI: 0.93, 11.43), P = 0.022], mean (S.E.M.) 13.0 (3.6) in pre-symptomatic individuals, compared with being negative for both as reference 6.8 (0.6) ( Table 2) , irrespective of adjustments of anti-CCP2 antibodies, RF, HLA-SE and smoking (data not shown). The combination of being positive for both RANKL and anti-CCP2 or RF or anti-cVim60-75 antibody positive did not yield a higher   FIG. 1 Concentrations of RANK ligand in pre-symptomatic individuals (n = 470) and controls (n = 96)
The mean concentrations are marked as a grey line. The cut-off value for RANKL positivity was set at the 98th percentile, based on receiver operating characteristic curve analysis (***P < 0.001). RANKL: RANK ligand. Larsen score at baseline in pre-symptomatic individuals compared with being negative for both of each different combination.
Discussion
In this study, we investigated the relationships between RANKL and ACPA and inflammatory makers, and their associations with bone destruction in individuals before the onset of the symptoms of RA. Furthermore, a temporal relationship between RANKL and the antibodies was suggested. A recent study has shown elevated concentrations of RANKL in both serum and the synovial tissue from untreated early RA patients, especially in ACPA-positive patients with RA [13] . In the present study, we report increased concentrations of RANKL being detectable several years before the onset of symptoms of RA. In line with the data from the study by Hensvold et al. [13] in RA, concentrations of RANKL were also found to be significantly increased in ACPA-positive RA patients compared with ACPA-negative individuals. In contrast to our data on individuals before symptom onset, no differences in concentrations of RANKL between pre-RA patients and controls was found in the study by van Schaardenburg et al. [23] . That study was based on a smaller group of individuals (n = 79) than ours, and there was no information on the methodology used to determine RANKL, for example, whether free or bound RANKL, or both were measured [23] . The relationship between RANKL and ACPA was not possible to separate from the relationship with RF because the frequencies of these factors were fairly low. However, in our recently published study on patients with early RA, the concentration of RANKL was increased in ACPA-positive patients irrespective of RF, which supports the importance of ACPA per se [14] .
The analyses of the time points of the first appearance of each of the antibodies and RANKL showed a time difference. These results suggested a much later appearance of RANKL positivity than that of anti-CCP2 antibodies and the classical ACPA response as analysed here, but also a later appearance than that of both RF and anti-CarP antibodies. Taken together, these results imply a time-dependent relationship between ACPA, anti-CarP antibodies and/or RF and RANKL production. If there is a direct effect of ACPA on the upregulation of RANKL production, which could be from a number of cells (e.g. osteoclasts, immune cells) or mediated via increased cytokine production [24] , is not evident from the results of this study. Based on data from the present study, we also report increased concentrations of IL-6, IL-10 and IP-10 and that these concentrations were correlated significantly with the concentrations of RANKL, this finding being in line with a previous report [25] . Levels of these and other cytokines representing Th1, Th2 and T-regulatory cells and chemokines have previously been shown by us and others to be increased before the onset of symptoms of RA [26, 27] . The cytokine IL-6 has been reported to induce RANKL expression, to trigger osteoclastogenesis and to promote bone formation [28] . Furthermore, the chemokine IP-10 has been suggested to enhance RANKL expression from osteoblastic stromal cells [25] . Osteoclast bone resorption was shown to be inhibited by the anti-inflammatory cytokine IL-10, as well as regulation of osteoblast bone formation [29] . Our results confirm that there are relationships between RANKL and IL-6, IL-10 or IP-10. However, we were unable to show a time-dependent development between these factors and the potential mechanisms behind these relationships (i.e. weather they are the results of osteoclast activity and/ or inflammation). However, we did not find an increased concentration of IL-8; this finding was unexpected because IL-8 had previously been shown to induce RANKL expression in osteoblasts and to stimulate osteoclastogenesis in RA patients [30] . In prior studies, RANKL, or the ratio of RANKL and osteoprotegerin, has been identified as a valuable predictor of radiological progression [13, 31, 32] . In the present study, we report that the concentration of RANKL was associated with a higher Larsen score at baseline in men. However, this result must be interpreted with care because the number of men with radiographical examination was few (47/158). The highest RANKL concentration could be found in anti-CarP and anti-cVim60-75 antibody-positive pre-symptomatic individuals [13] . Although the RANKL concentration was increased in ACPA-positive individuals, no association in radiological findings could be explored for the combination of ACPA and RANKL as was the case for the combination of RANKL and anti-CarP antibody positivity. In pre-symptomatic individuals, the combination was associated with a higher Larsen score at baseline compared with being negative for both as a reference irrespective of adjustment for anti-CCP2 antibodies. These results suggest a novel link between RANKL and anti-CarP antibodies and radiological changes in early RA, a process that is suggested to begin several years before the onset of symptoms of RA.
Our study has some limitations; for example, the samples analysed were identified from different population surveys, and not collected on a regular basis. Unfortunately, there is a lack of complete data from all of the analyses undertaken and radiological examinations, which will culminate in a reduced number of data points for sub-group analyses.
We believe this study to be the largest populationbased study in which relationships have been investigated between RANKL, ACPA, anti-CarP antibodies and inflammatory makers (measured as pro-inflammatory cytokines/ chemokines) and their associations with bone destruction in pre-symptomatic individuals. RANKL and anti-CarP IgG were analysed before symptom onset, and X-ray was at diagnosis of RA. RANKL: RANK ligand.
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